Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal

investors.com/news/technology/cidara-therapeutics-stock-merck-takeover

shares doubled, and then some, on Friday after Merck (MRK) agreed to buy the biotech company for $9.2 billion.
The deal is "nothing to sneeze at," RBC Capital Markets analyst Brian Abrahams said in a report. It values Cidara stock at $221.50 per share, representing a roughly 110% premium…

This story appeared on investors.com, 2025-11-14 17:17:42.487000.
The Entire Business World on a Single Page. Free to Use →